Statistik Asas
| LEI | 549300NOUZGB2ZNVJ794 |
| CIK | 910267 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Titan Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: August 26, 2025 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14 (a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-13341 Titan Pharmaceuticals |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14 (a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 27, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 24, 2025 by and between TITAN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Purchaser (as defined below) (the “Investor”). WITNESSETH WHEREAS: A. In connection with the Securities Purchase Agreement between the parties of even date (the “Securities Purchase Agreem |
|
| June 27, 2025 |
Certificate of Designations, Preferences and Rights of Series C Convertible Preferred Stock. Exhibit 4.1 TITAN PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATIONS, PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Chay Weei Jye, does hereby certify that: 1. He is the Chief Executive Officer of Titan Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation i |
|
| June 27, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 24, 2025, between TITAN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 24, 2025 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13341 94-3171940 (State or other jurisdiction of incorporation) (Commissi |
|
| June 27, 2025 |
Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock Exhibit 99.1 Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock NEW YORK, June 27, 2025 - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today that, pursuant to a securities purchase agreement (the “Purchase Agreement”) with Blue Harbour Asset Management L.L.C-FZ (“Blue Harbour”), it has completed a private placement of the Co |
|
| June 18, 2025 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: June 16, 2025 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| June 3, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2025 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13341 94-3171940 (State or other jurisdiction of incorporation) (Commissio |
|
| June 3, 2025 |
Exhibit 99.1 Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd. NEW YORK, June 3, 2025 - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form F-4 in connection with |
|
| June 3, 2025 |
Exhibit 99.1 Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd. NEW YORK, June 3, 2025 - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form F-4 in connection with |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2025 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13341 94-3171940 (State or other jurisdiction of incorporation) (Commissio |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2025 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13341 94-3171940 (State or other jurisdiction of incorporation) (Commissio |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-13341 Titan Pharmaceutical |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide |
|
| April 22, 2025 |
Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock Exhibit 99.1 Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) – Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today that, pursuant to a securities purchase agreement (the “Purchase Agreement”) with Blue Harbour Asset Management L.L.C-FZ (“Blue Harbour”), it has completed a private |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2025 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13341 94-3171940 (State or other jurisdiction of incorporation) (Commiss |
|
| April 1, 2025 |
Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock. Exhibit 4.1 TITAN PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATIONS, PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Chay Weei Jye, does hereby certify that: 1. He is the Chief Executive Officer of Titan Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation i |
|
| April 1, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 29, 2025 by and between TITAN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Purchaser (as defined below) (the “Investor”). WITNESSETH WHEREAS: A. In connection with the Securities Purchase Agreement between the parties of even date (the “Securities Purchase Agree |
|
| April 1, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 29, 2025, between TITAN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| April 1, 2025 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 26, 2025 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13341 94-3171940 (State or other jurisdiction of incorporation) (Commiss |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-13341 TITAN PHARMAC |
|
| March 20, 2025 |
Exhibit 19.1 TITAN PHARMACEUTICALS, INC. INSIDER TRADING POLICY ALL EMPLOYEES, OFFICERS, DIRECTORS, SCIENTIFIC ADVISORS, AND CONSULTANTS OF TITAN PHARMACEUTICALS, INC. OR ANY OF TITAN PHARMACEUTICALS’ SUBSIDIARY CORPORATIONS (THE “SUBSIDIARIES”) ARE PROHIBITED FROM TRADING (EITHER DIRECTLY OR INDIRECTLY), AND FROM “TIPPING” OTHERS TO TRADE, IN TITAN PHARMACEUTICALS, INC SECURITIES WHEN THEY KNOW M |
|
| March 20, 2025 |
Employment Agreement, dated March 20, 2025, between Titan Pharmaceuticals, Inc. and Chay Weei Jye. Exhibit 10.20 EMPLOYMENT AGREEMENT This Agreement (the “Agreement”), is made and entered into as of March 20, 2025 (the “Agreement Date”), by and between Titan Pharmaceuticals, Inc. (the “Company”), and Chay Weei Jye (the “Executive”, and together with the Company, the “Parties”). NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth below, it is hereby covenanted and a |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 3, 2025 Titan Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-13341 94-3171940 (State or other jurisdiction of incorporation) (Commiss |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-13341 Titan Pharmaceut |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 2, 2024 Titan Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-13341 94-3171940 (State or other jurisdiction of incorporation) (Commis |
|
| November 27, 2024 |
Letter from WithumSmith+Brown, PC to the Securities and Exchange Commission dated November 27, 2024 Exhibit 16.1 November 27, 2024 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Titan Pharmaceuticals, Inc.’s statements included under Item 4.01 of its Form 8-K dated November 27, 2024. We agree with the statements concerning our Firm under Item 4.01 related to our resignation. We are not in position to ag |
|
| November 27, 2024 |
Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq Exhibit 99.1 Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq NEW YORK, NY, November 27, 2024 /PRNewswire/ - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance w |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2024 Titan Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-13341 94-3171940 (State or other jurisdiction of incorporation) (Commi |
|
| November 15, 2024 |
PART I — REGISTRANT INFORMATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION SEC FILE NUMBER Washington, D.C. 20549 001-13341 FORM 12b-25 CUSIP NUMBER 888314705 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☑ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 Nothing in this form shall be construed to imply that the Commission has verified any information conta |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2024 Titan Pharmaceuticals Inc. (Exact name of registrant as specified in its charter)94-3171940 Delaware 001-13341 94-317940 (State or other jurisdiction of incorporation |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2024 Titan Pharmaceuticals Inc. (Exact name of registrant as specified in its charter)94-3171940 Delaware 001-13341 94-317940 (State or other jurisdiction of incorporation |
|
| August 21, 2024 |
TTNP / Titan Pharmaceuticals, Inc. / Sire Group Ltd. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 888314705 (CUSIP Number) Dato’ Seow Gim Shen The Sire Group Ltd. No. 4, Franky Building, Providence Industrial Estate, Mahe, Seychelles T |
|
| August 19, 2024 |
Exhibit 2.1 EXECUTION VERSION MERGER AND CONTRIBUTION AND SHARE EXCHANGE AGREEMENT by and among BSKE LTD., TITAN PHARMACEUTICALS, INC., TTNP MERGER SUB, INC. and KE SDN BHD dated as of August 19, 2024 TABLE OF CONTENTS Page Article I DEFINITIONS 2 Section 1.1 Definitions 2 Section 1.2 Construction 16 Section 1.3 Knowledge 17 Article II TRANSACTIONS; CLOSING 17 Section 2.1 Pre-Closing Actions 17 Se |
|
| August 19, 2024 |
Exhibit 2.1 EXECUTION VERSION MERGER AND CONTRIBUTION AND SHARE EXCHANGE AGREEMENT by and among BSKE LTD., TITAN PHARMACEUTICALS, INC., TTNP MERGER SUB, INC. and KE SDN BHD dated as of August 19, 2024 TABLE OF CONTENTS Page Article I DEFINITIONS 2 Section 1.1 Definitions 2 Section 1.2 Construction 16 Section 1.3 Knowledge 17 Article II TRANSACTIONS; CLOSING 17 Section 2.1 Pre-Closing Actions 17 Se |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 19, 2024 Titan Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) 94-3171940 Delaware 001-13341 94-317940 (State or other jurisdiction of incorporation |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 19, 2024 Titan Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) 94-3171940 Delaware 001-13341 94-317940 (State or other jurisdiction of incorporation |
|
| August 19, 2024 |
TITAN PHARMACEUTICALS ENTERS INTO MERGER AGREEMENT WITH KE SDN. BHD. Exhibit 99.1 TITAN PHARMACEUTICALS ENTERS INTO MERGER AGREEMENT WITH KE SDN. BHD. NEW YORK, NY, August 19, 2024 /GLOBE NEWSWIRE/ - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”). The Merger Agreement was approved by |
|
| August 19, 2024 |
TITAN PHARMACEUTICALS ENTERS INTO MERGER AGREEMENT WITH KE SDN. BHD. Exhibit 99.1 TITAN PHARMACEUTICALS ENTERS INTO MERGER AGREEMENT WITH KE SDN. BHD. NEW YORK, NY, August 19, 2024 /GLOBE NEWSWIRE/ - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”). The Merger Agreement was approved by |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-13341 Titan Pharmaceuticals |
|
| August 15, 2024 |
PART I — REGISTRANT INFORMATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION SEC FILE NUMBER Washington, D.C. 20549 001-13341 FORM 12b-25 CUSIP NUMBER 888314705 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☑ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 Nothing in this form shall be construed to imply that the Commission has verified any information contained |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-13341 Titan Pharmaceutical |
|
| April 26, 2024 |
Titan Pharmaceuticals, Inc. 400 Oyster Point Blvd., Suite 505 South San Francisco, California Titan Pharmaceuticals, Inc. 400 Oyster Point Blvd., Suite 505 South San Francisco, California April 26, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Titan Pharmaceuticals, Inc. Request to Withdraw Registration Statement on Form S-1 Filed June 23, 2023 File No. 333-272910 Ladies and Gentlemen: Pursuant to Rule 4 |
|
| April 5, 2024 |
TTNP / Titan Pharmaceuticals, Inc. / Sire Group Ltd. - SC 13D/A Activist Investment SC 13D/A 1 titanpharmasc13da1.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 888314705 (CUSIP Number) Seow Gim Shen The Sire Group Ltd. No. 4, Franky Building, Providence |
|
| April 3, 2024 |
Resignation Agreement, dated April 2, 2024, between the Company and David Lazar. Exhibit 10.3 SETTLEMENT AGREEMENT AND GENERAL AND MUTUAL RELEASE This Settlement Agreement and General and Mutual Release (the “Agreement”) is on this 2nd day of April by and between Titan Pharmaceuticals, Inc. (the “Company”) and David Lazar (the “Executive”), collectively known herein as the “Parties.” WHEREAS, the Executive and the Company executed an employment agreement, dated December 14, 20 |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 2, 2024 TITAN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-13341 94-317940 94-3171940 (State or other jurisdiction of incorporation) |
|
| April 3, 2024 |
Agreement, dated April 2, 2024, between the Company and Avraham Ben-Tzvi. Exhibit 10.2 AGREEMENT This Agreement (the “Agreement”) is made on this 2nd day of April by and between Titan Pharmaceuticals, Inc. (the “Company”) and Avraham Ben-Tzvi (the “Director”), collectively known herein as the “Parties.” WHEREAS, the Director was elected to act as a Member of the Board of Directors of the Company (the “Services”). WHEREAS, the Director has provided the Services above and |
|
| April 3, 2024 |
Exhibit 10.1 FORM OF SETTLEMENT AGREEMENT AND GENERAL AND MUTUAL RELEASE This Settlement Agreement and General and Mutual Release (the “Agreement”) is on this 2nd day of April by and between Titan Pharmaceuticals, Inc. (the “Company”) and [] (the “Director”), collectively known herein as the “Parties.” WHEREAS, the Director was elected to act as a Member of the Board of Directors of the Company (t |
|
| April 3, 2024 |
Resignation Agreement, dated April 2, 2024, between the Company and Katherine Beebe DeVarney. Exhibit 10.4 SETTLEMENT AGREEMENT AND GENERAL AND MUTUAL RELEASE This Settlement Agreement and General and Mutual Release (the “Agreement”) is on this 2nd day of April by and between Titan Pharmaceuticals, Inc. (the “Company”) and Katherine Beebe DeVarney, Ph.D. (the “Executive”), collectively known herein as the “Parties.” WHEREAS, the Executive and the Company executed an employment agreement da |
|
| April 1, 2024 |
Exhibit 97.1 TITAN PHARMACEUTICALS, INC. DODD-FRANK CLAWBACK POLICY The Board of Directors (the “Board”) of Titan Pharmaceuticals, Inc. (the “Company”) has adopted this clawback policy (the “Policy”) as a supplement to any other clawback policies in effect now or in the future at the Company to provide for the recovery of erroneously awarded Incentive-Based Compensation from Executive Officers. Th |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: April 1, 2024 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-13341 TITAN PHARMAC |
|
| March 21, 2024 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: March 18, 2024 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| February 8, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: February 1, 2024 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: January 24, 2024 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: January 11, 2024 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| January 8, 2024 |
Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 09:49 AM 01/08/2024 FILED 09:49 AM 01/08/2024 SR 20240054446 – File Number 2287466 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TITAN PHARMACEUTICALS, INC. Titan Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: January 8, 2024 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| December 28, 2023 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: December 27, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| December 28, 2023 |
TITAN PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT AND RATIO Exhibit 99.1 TITAN PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT AND RATIO SOUTH SAN FRANCISCO, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s common stock, which will be effective following the filing of an amendment to the Compan |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide |
|
| November 15, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: November 7, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| November 14, 2023 |
Convertible Promissory Note between Titan Pharmaceuticals, Inc. and Choong Choon Hau* Exhibit 10.4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-13341 Titan Pharmaceut |
|
| October 24, 2023 |
As filed with the Securities and Exchange Commission on October 24, 2023 As filed with the Securities and Exchange Commission on October 24, 2023 Registration Statement No. |
|
| October 24, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Titan Pharmaceuticals, Inc. |
|
| October 16, 2023 |
Exhibit 99.1 TITAN PHARMACEUTICALS ANNOUNCES APPOINTMENT OF DATO’ SEOW GIM SHEN AND BRYNNER CHIAM TO THE COMPANY’S BOARD OF DIRECTORS SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) is pleased to announce the appointments of Dato’ Seow Gim Shen and Brynner Chiam to the Company’s Board of Directors , effective October 12, 2023. M |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: October 12, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| October 4, 2023 |
TTNP / Titan Pharmaceuticals, Inc. (de) / Sire Group Ltd. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 888314 (CUSIP Number) Seow Gim Shen The Sire Group Ltd. No. 4, Franky Building, Providence Industrial Estate, Mahe, Seychelles] Tel No.: + |
|
| October 4, 2023 |
Promissory Note, dated September 13, 2023, made by Sire to the Issuer, previously filed. EX-99.4 2 titanpharmaex99-4.htm EXHIBIT 4 Exhibit 4 PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, Purchaser (as defined in the Purchase Agreement) (“Maker”), hereby unconditionally promises to pay to the order of TITAN PHARMACEUTICALS, INC., a Delaware corporation (“Holder,” and together with Maker, the “Parties”), the principal amount of USD $4,500, |
|
| October 4, 2023 |
Joint Filing Agreement, dated September 25, 2023, between Sire and Seow Gim Shen, previously filed. EX-99.5 3 titanpharmaex99-5.htm EXHIBIT 5 Exhibit 5 JOINT FILING AGREEMENT In accordance with Rule 13d-k(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the securities of Titan Pharmaceuticals, Inc. and further agree that this Joint Fil |
|
| September 19, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 13, 2023 by and between TITAN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Purchaser (as defined below) (the “Investor”). WITNESSETH WHEREAS: A. In connection with the Securities Purchase Agreement between the parties of even date (the “Securities Purchase A |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: September 13, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| September 19, 2023 |
Certificate of Designations, Preferences and Rights of Series AA Convertible Preferred Stock. Exhibit 4.1 TITAN PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATIONS, PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES AA CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, David Lazar, does hereby certify that: 1. He is the Chief Executive Officer of Titan Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is |
|
| September 19, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 13, 2023, between TITAN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”)). WHEREAS, subject to the terms and c |
|
| September 18, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 13, 2023, between TITAN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”)). WHEREAS, subject to the terms and c |
|
| September 18, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 13, 2023 by and between TITAN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Purchaser (as defined below) (the “Investor”). WITNESSETH WHEREAS: A. In connection with the Securities Purchase Agreement between the parties of even date (the “Securities Purchase A |
|
| September 18, 2023 |
Exhibit 4.1 TITAN PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATIONS, PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES AA CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, David Lazar, does hereby certify that: 1. He is the Chief Executive Officer of Titan Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: September 13, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: September 1, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| September 8, 2023 |
TITAN PHARMACEUTICALS, INC. UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION Exhibit 99.1 TITAN PHARMACEUTICALS, INC. UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION On September 1, 2023, Titan Pharmaceuticals, Inc. (“Titan” or the “Company”) completed the sale of certain ProNeura Assets, for approximately $2.0 million, comprised of approximately $0.5 million of cash proceeds, the Cash Note for $0.5 million and the Escrow Note for $1.0 million. The sale constitutes a s |
|
| August 30, 2023 |
Exhibit 10.1 *** Certain identified information has been excluded (denoted by the symbol “[****]”) from the exhibit because such information is both (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. AMENDMENT AND EXTENSION AGREEMENT THIS AMENDMENT AND EXTENSION AGREEMENT (the “Agreement”) is made and entered into as of August 25, 2023, by and betwe |
|
| August 30, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: August 25, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| August 14, 2023 |
Convertible Promissory Note between Titan Pharmaceuticals, Inc. and Choong Choon Hau Exhibit 10.4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-13341 Titan Pharmaceuticals |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: July 20, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| July 28, 2023 |
Unsecured Promissory Note between Titan Pharmaceuticals, Inc. and David E. Lazar Exhibit 10.2 July 20, 2023 $250,000.00 UNSECURED PROMISSORY NOTE FOR GOOD AND VALUABLE CONSIDERATION, receipt of which is hereby acknowledged, the undersigned, Titan Pharmaceuticals, Inc., a Delaware corporation (the “Maker”), hereby promises to pay to David E. Lazar, a natural person with an address at Villa 1, 14-43rd Street Jumeirah 2, Dubai, U.A.E (together with his successors, transferees and |
|
| July 28, 2023 |
Exhibit 10.1 *** Certain identified information has been excluded (denoted by the symbol “[****]”) from the exhibit because such information is both (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. ASSET PURCHASE AGREEMENT by and between TITAN PHARMACEUTICALS, INC. and FEDSON, INC. July 26, 2023 EXHIBITS Exhibit A - Bill of Sale and Assignment and |
|
| July 28, 2023 |
Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets Exhibit 99.1 Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets Company to receive $2 million in upfront payments, with the potential to receive up to $50 million in milestone payments and single digit royalty payments on future net sales San Francisco, Calif., July 27, 2023 - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that it has entered int |
|
| July 21, 2023 |
TTNP / Titan Pharmaceuticals, Inc. (de) / Choong Choon Hau Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No.) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) TITAN PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 888314606 (CUSIP Number) Choong Choon Hau No. 23 |
|
| July 21, 2023 |
Share Transfer Agreement dated June 21, 2023 Exhibit 99.1 SHARE TRANSFER AGREEMENT TRANSFER AGREEMENT (this “Agreement”), effective as of June 21, 2023 (the “Effective Date”), is entered into by and between (i) Mr. David Lazar of Villa 1, 14-43rd Street, Jumeirah 2, Dubai, United Arab Emirates (the “Selling Shareholder”)1, (ii) Choong Choon Hau, of Emerald Heights 23 Lrg Terubong Ria 2, Paya Terubong, 11060 Pulau Pinang (the “Purchaser”); an |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: July 6, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: June 29, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| June 23, 2023 |
As filed with the Securities and Exchange Commission on June 23, 2023 As filed with the Securities and Exchange Commission on June 23, 2023 Registration No. |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 888314606 (CUSIP Number) DAVID E. LAZAR Vill |
|
| June 23, 2023 |
Share Transfer Agreement, dated June 21, 2023. Exhibit 99.3 SHARE TRANSFER AGREEMENT TRANSFER AGREEMENT (this “Agreement”), effective as of June 21, 2023 (the “Effective Date”), is entered into by and between (i) Mr. David Lazar of Villa 1, 14-43rd Street, Jumeirah 2, Dubai, United Arab Emirates (the “Selling Shareholder”)1, (ii) Choong Choon Hau, of Emerald Heights 23 Lrg Terubong Ria 2, Paya Terubong, 11060 Pulau Pinang (the “Purchaser”); an |
|
| June 23, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Titan Pharmaceuticals, Inc. |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: June 5, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-13341 Titan Pharmaceutical |
|
| May 15, 2023 |
Form of Amendment to Employment Agreement with Kate DeVarney Exhibit 10.18 2023 AMENDMENT TO EMPLOYMENT AGREEMENT 2023 AMENDMENT dated March , 2022 between Titan Pharmaceuticals, Inc. (the “Company”) and Katherine Beebe DeVarney, Ph.D. (“Executive”). WHEREAS, the Company and Executive are parties to an employment agreement dated November 1, 2018 (the “Employment Agreement”); and WHEREAS, the Company and Executive wish to amend the Employment Agreement to re |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: April 5, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-13341 TITAN PHARMAC |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: March 16, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: February 28, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: February 8, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: January 4, 2023 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| December 15, 2022 |
Titan Pharmaceuticals Provides Shareholder Update Exhibit 99.1 Titan Pharmaceuticals Provides Shareholder Update ● Signs Non-Binding Letter of Intent for Transformational Transaction ● Continues to Make Substantial Progress on Strategic Transactions Including Sale of Existing Assets San Francisco, Calif., December 15, 2022 - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) is pleased to report that it has entered a non-bindin |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 888314606 (CUSIP Number) DAVID E. LAZAR Vill |
|
| December 15, 2022 |
Exhibit 99.2 EMPLOYMENT AGREEMENT This Agreement (the “Agreement”), is made and entered into as of December 14, 2022 (the “Agreement Date”), by and between Titan Pharmaceuticals, Inc. (the “Company”), and David Lazar (the “Executive”, and together with the Company, the “Parties”) NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth below, it is hereby covenanted and ag |
|
| December 15, 2022 |
Press Release, dated December 15, 2022. EX-99.1 2 titanpharmaex99-1.htm PRESS RELEASE, DATED DECEMBER 15, 2022 Exhibit 99.1 Titan Pharmaceuticals Provides Shareholder Update ● Signs Non-Binding Letter of Intent for Transformational Transaction ● Continues to Make Substantial Progress on Strategic Transactions Including Sale of Existing Assets San Francisco, Calif., December 15, 2022 - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: December 13, 2022 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| December 15, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Agreement (the “Agreement”), is made and entered into as of December 14, 2022 (the “Agreement Date”), by and between Titan Pharmaceuticals, Inc. (the “Company”), and David Lazar (the “Executive”, and together with the Company, the “Parties”) NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth below, it is hereby covenanted and ag |
|
| December 12, 2022 |
Titan Pharmaceuticals Announces Licensing Agreement with Ocular Therapeutix Exhibit 99.1 Titan Pharmaceuticals Announces Licensing Agreement with Ocular Therapeutix San Francisco, Calif., December 12, 2022 - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (?Titan? or the ?Company?) today announced that it has granted an exclusive license to Ocular Therapeutix (NASDAQ: OCUL) (?Ocular?) pertaining to certain patent applications for ophthalmic uses in both humans and nonhuman ani |
|
| December 12, 2022 |
Exhibit 10.1 Execution Version LICENSE AGREEMENT between TITAN PHARMACEUTICALS, INC. and OCULAR THERAPEUTIX, INC. Dated as of December 6, 2022 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 ARTICLE 2 GRANT OF RIGHTS 8 2.1 Grants to Ocular 8 2.2 Sublicenses 8 2.3 Retention of Rights; Limitations Applicable to License Grants 9 ARTICLE 3 DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES; REPRE |
|
| December 12, 2022 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: December 6, 2022 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-13341 Titan Pharmaceut |
|
| November 14, 2022 |
Form of Stock Option Agreement Exhibit 10.1 STAND-ALONE STOCK OPTION AGREEMENT THIS STAND-ALONE STOCK OPTION AGREEMENT (this ?Agreement?) dated as of the 15th day of September, 2022 by and between Titan Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and [?] (the ?Optionee?). RECITALS WHEREAS, the Company has adopted and maintains the Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan effective August |
|
| November 14, 2022 |
Fifth Amended and Restated 2015 Omnibus Equity Incentive Plan (subject to stockholder approval)(28) Exhibit 10.2 TITAN PHARMACEUTICALS, INC. FIFTH AMENDED AND RESTATED 2015 OMNIBUS EQUITY INCENTIVE PLAN As Amended [?], 2022 ARTICLE I PURPOSE The purpose of this Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan (the ?Plan?) is to benefit Titan Pharmaceuticals, Inc., a Delaware corporation (the ?Company?) and its stockholders, by assisting the Company to attract, retain and provide in |
|
| September 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 15, 2022 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13341 94-3171940 (State or other jurisdiction of incorporation) (Com |
|
| September 21, 2022 |
Form of Stock Option Agreement(27) Exhibit 10.1 STAND-ALONE STOCK OPTION AGREEMENT THIS STAND-ALONE STOCK OPTION AGREEMENT (this ?Agreement?) dated as of the 15th day of September, 2022 by and between Titan Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and [?] (the ?Optionee?). RECITALS WHEREAS, the Company has adopted and maintains the Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan effective August |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: August 16, 2022 (Date of earliest event reported) TITAN PHARMACEUTICALS, INC. |
|
| August 17, 2022 |
SC 13D/A 1 titanpharmasc13da.htm AMENDMENT NO. 3 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title |
|
| August 16, 2022 |
Titan Pharmaceuticals Announces Board Expansion and Management Changes Exhibit 99.1 Titan Pharmaceuticals Announces Board Expansion and Management Changes SOUTH SAN FRANCISCO, Calif., August 16, 2022 /PRNewswire/ ? Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (?Titan? or the ?Company?) today announced that it has expanded its Board of Directors (the ?Board?) from five (5) to eleven (11) and appointed six new directors following their election at its special meeting of |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2022 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commis |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 5, 2022 |
Form of Amendment to Employment Agreement with Marc Rubin(26) Exhibit 10.1 AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT AMENDMENT No. 3 dated as of August 3, 2022 between Titan Pharmaceuticals, Inc. (the ?Company?) and Marc Rubin (?Executive?). WHEREAS, the Company and Executive are parties to an employment agreement dated April 2, 2019 (as amended in February 2021 and October 2021, the ?Employment Agreement?); and WHEREAS, the Company and Executive wish to amend |
|
| August 5, 2022 |
Form of Amendment to Employment Agreement with Kate DeVarney(26) Exhibit 10.2 AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT AMENDMENT No. 2 dated as of August 3, 2022 between Titan Pharmaceuticals, Inc. (the ?Company?) and Katherine Beebe DeVarney (?Executive?). WHEREAS, the Company and Executive are parties to an employment agreement dated November 1, 2018 (as amended in February 2021, the ?Employment Agreement?); and WHEREAS, the Company and Executive wish to amend |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 2, 2022 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commiss |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 21, 2022 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commissi |
|
| July 22, 2022 |
PRRN14A 1 titanpharmaprrn14a.htm PRRN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate bo |
|
| July 14, 2022 |
PREN14A 1 titanpharmapren14a.htm PREN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box |
|
| July 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 12, 2022 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commissi |
|
| July 11, 2022 |
DFAN14A 1 titanpharmaincdfan14a.htm DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate |
|
| July 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 8, 2022 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commissio |
|
| July 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 2)1 Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 888314606 (CUSIP Number) DAVID E. LAZAR Vill |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 5, 2022 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commissio |
|
| July 5, 2022 |
Amendment to the By-laws of the Registrant dated July 5, 2022(25) Exhibit 3.1 AMENDMENT TO THE BYLAWS OF TITAN PHARMACEUTICALS, INC. (Effective as of July 5, 2022) 1. Article II, Section 5 of the Bylaws, as amended (the ?Bylaws?), of Titan Pharmaceuticals, Inc. (the ?Corporation?) is hereby amended and restated in its entirety as follows: Section 5. Special meetings of the stockholders, for any purpose or purposes, unless otherwise prescribed by statute or by th |
|
| July 5, 2022 |
Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant Exhibit 99.1 Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant SOUTH SAN FRANCISCO, Calif., July 5, 2022 /PRNewswire/ - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (?Titan? or the ?Company?) today announced that the U.S. Food and Drug Administration (?FDA?) has cleared its Investigational New Drug (?IND?) application for a Phase 1 study of its six-month or longe |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 888314606 (CUSIP Number) DAVID E. LAZAR Vill |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 1, 2022 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commissio |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 6, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2022 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commission |
|
| April 25, 2022 |
Joint Filing Agreement, dated April 25, 2022. Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par value, of Titan Pharmaceuticals, Inc., a Delaware corporation. T |
|
| April 25, 2022 |
TTNP / Titan Pharmaceuticals, Inc. / Activist Investing LLC - THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. )1 Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 888314606 (CUSIP Number) DAVID E. LAZAR C/O A |
|
| April 25, 2022 |
Press Release, dated April 25, 2022. Exhibit 99.1 Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc. NEW YORK, April 25, 2022, Activist Investing LLC (together with its affiliates, ?Activist Investing? or ?we?), today filed a Schedule 13D announcing its acquisition of approximately 5.6% of the common stock outstanding of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (?TTNP? or the ?Company?). David E. La |
|
| April 5, 2022 |
PROSPECTUS 6,004,855 shares of common stock Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-262614 PROSPECTUS 6,004,855 shares of common stock This prospectus of relates to the resale from time to time of up to 6,004,855 shares of our common stock, $0.001 par value per share, including 5,953,834 issuable upon the exercise of outstanding warrants held by the selling stockholders named herein (the ?Selling Stockholders?). The |
|
| April 4, 2022 |
As filed with the Securities and Exchange Commission on April 4, 2022 As filed with the Securities and Exchange Commission on April 4, 2022 Registration No. |
|
| April 4, 2022 |
EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Titan Pharmaceuticals, Inc. |
|
| March 31, 2022 |
March 31, 2022 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: Titan Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-262614 Ladies and Gentlemen: Titan Pharmaceuticals, Inc. hereby requests that the effective date of the above-captioned Registration Statement be accelerated to 4:00 p.m. on Monday, April 4, 2022, or as soon thereafter as pr |
|
| March 31, 2022 |
March 31, 2022 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: Titan Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-262614 Ladies and Gentlemen: Titan Pharmaceuticals, Inc. hereby requests that the effective date of the above-captioned Registration Statement be accelerated to 4:00 p.m. on Thursday, March 31, 2022, or as soon thereafter as |
|
| March 28, 2022 |
EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Titan Pharmaceuticals, Inc. |
|
| March 28, 2022 |
As filed with the Securities and Exchange Commission on March 28, 2022 As filed with the Securities and Exchange Commission on March 28, 2022 Registration No. |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 1 Under the Securities Exchange Act of 1934 Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 888314507 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 10, 2022 |
EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Titan Pharmaceuticals, Inc. |
|
| February 10, 2022 |
Power of Attorney (included on the signature page of this Registration Statement) As filed with the Securities and Exchange Commission on February 10, 2022 Registration No. |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 2, 2022 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commi |
|
| February 3, 2022 |
Exhibit 10.2 February 2, 2022 Marc Rubin, M.D. Executive Chairman Titan Pharmaceuticals, Inc. 400 Oyster Point Blvd., Suite 505 South San Francisco, CA 94080 Dear Dr. Rubin: This letter (the ?Agreement?) constitutes the agreement between Maxim Group LLC (?Maxim?) (the ?Placement Agent?) and Titan Pharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware (the ?Company?), |
|
| February 3, 2022 |
Form of February 2022 Private Pre-Funded Warrant(24) Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 3, 2022 |
1,100,000 Shares of Common Stock Pre-Funded Warrants to Purchase 2,274,242 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-230742 Prospectus Supplement (to Prospectus dated April 24, 2019) 1,100,000 Shares of Common Stock Pre-Funded Warrants to Purchase 2,274,242 Shares of Common Stock We are offering 1,100,000 shares of our common stock, $0.001 par value per share, and pre-funded warrants to purchase 2,274,242 shares of our common stock (and the shares of common s |
|
| February 3, 2022 |
Exhibit 99.1 Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market SOUTH SAN FRANCISCO, Calif., Feb. 2, 2022 /PRNewswire/ - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (?Titan? or the ?Company?) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its c |
|
| February 3, 2022 |
Form of February 2022 Securities Purchase Agreement(24) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of February 2, 2022, between Titan Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and cond |
|
| February 3, 2022 |
Form of February 2022 Placement Warrant(24) Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 3, 2022 |
Form of February 2022 Registered Pre-Funded Warrant(24) EX-4.1 2 tm225246d1ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 PRE- FUNDED COMMON STOCK PURCHASE WARRANT Titan Pharmaceuticals, Inc. Warrant Shares: [ Initial Exercise Date: February , 2022 Issue Date: February , 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on ex |
|
| January 24, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 888314606 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 30, 2021 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Comm |
|
| December 29, 2021 |
Amendment to the By-laws of the Registrant dated December 29, 2021 (23) Exhibit 3.1 AMENDMENT TO THE BYLAWS OF TITAN PHARMACEUTICALS, INC. (Effective as of December 29, 2021) Article II Section 8 of the Bylaws of Titan Pharmaceuticals, Inc. (the ?Corporation?) is hereby amended and restated in its entirety as follows: Section 8. At any meeting of stockholders of the Corporation, the presence, in person or by proxy, of the holders of record of thirty-four percent (34%) |
|
| December 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 29, 2021 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Comm |
|
| December 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary proxy statement ? Confidential, For use of |
|
| December 22, 2021 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 17, 2021 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Comm |
|
| December 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 17, 2021 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Comm |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 13, 2021 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Comm |
|
| December 14, 2021 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 13, 2021 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Comm |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary proxy statement ? Confidential, For use of |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2021 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commi |
|
| November 9, 2021 |
SUSTAINED ANTI-PRURITIC EFFECT OF TITAN’S TP-2021 IMPLANT REPORTED TODAY AT NEUROSCIENCE 2021 Exhibit 99.2 SUSTAINED ANTI-PRURITIC EFFECT OF TITAN?S TP-2021 IMPLANT REPORTED TODAY AT NEUROSCIENCE 2021 SOUTH SAN FRANCISCO, CA ? November 8, 2021 ? Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (?Titan? or the ?Company?) announced that, in a presentation given today at the Society for Neuroscience 2021 Meeting, Ben Land, Ph.D., Research Assistant Professor at the University of Washington?s Depart |
|
| November 9, 2021 |
Exhibit 99.1 Sustained anti-pruritic effect in mice with TP- 2021, a kappa opioid agonist peptide, delivered by subdermal ProNeura? Implants B. B. Land1, S. Sreedharan2, R. Patel2, T. Beck3, K. DeVarney2, M. Rubin2, *C. Chavkin1; 1Pharmacol., Univ. of Washington, Seattle, WA; 2Titan Pharmaceuticals, South San Francisco, CA; 3Med. Univ. of South Carolina, Charleston, SC KAPPA OPIOID RECEPTOR AGONIS |
|
| November 5, 2021 |
our Definitive Proxy Statement filed with the SEC on November 5, 2021; ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary proxy statement ? ? Confidential, For us |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 27, 2021 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commi |
|
| October 28, 2021 |
Amendment to Employment Agreement between the Registrant and Marc Rubin(22) Exhibit 10.1 AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT AMENDMENT No. 2 dated October 27, 2021 between Titan Pharmaceuticals, Inc. (the ?Company?) and Marc Rubin (?Executive?). WHEREAS, the Company and Executive are parties to an employment agreement dated April 2, 2019 (as amended in February 2021, the ?Employment Agreement?); and WHEREAS, the Company and Executive wish to extend the Employment Agre |
|
| October 26, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 25, 2021 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commi |
|
| October 26, 2021 |
Exhibit 99.1 Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries SOUTH SAN FRANCISCO, CA ? October 25, 2021 ? Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (?Titan? or the ?Company?) today announced that it has received funding from the Bill & Melinda Gates Foundation to support the demonstration of its ability to d |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 26, 2021 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 23, 2021 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commissi |
|
| July 26, 2021 |
Letter from OUM & Co., LLP to the Securities and Exchange Commission dated July 26, 2021. Exhibit 16.1 July 26, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549-7561 Ladies and Gentlemen: We have read Titan Pharmaceuticals, Inc.?s statements included under Item 4.01 of its Form 8-K dated July 26, 2021, and are in agreement with the statements contained therein concerning our firm in response to Item 304(a) of Regulation S-K. Very truly yours, /s/ OUM & Co |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-13341 Titan Pharmaceutical |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-13341 TITAN PHARMAC |
|
| February 8, 2021 |
PROSPECTUS 2,725,000 shares of common stock Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-252482 PROSPECTUS 2,725,000 shares of common stock This prospectus of relates to the resale from time to time of up to 2,725,000 shares of our common stock, $0.001 par value per share, issuable upon the exercise of outstanding warrants (the “Placement Warrants”) held by the selling stockholders named herein (the “Selling Stockholders” |
|
| February 4, 2021 |
Financial Statements and Exhibits, Other Events 8-K 1 tm215319d18k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 1, 2021 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) |
|
| February 4, 2021 |
February 4, 2021 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: Titan Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-252482 Ladies and Gentlemen: Titan Pharmaceuticals, Inc. hereby requests that the effective date of the above-captioned Registration Statement be accelerated to 4:00 p.m. on Friday, February 5, 2021, or as soon thereafter |
|
| February 4, 2021 |
As filed with the Securities and Exchange Commission on February 4, 2021 Registration No. |
|
| February 4, 2021 |
EX-99.1 2 tm215319d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program South San Francisco, CA – February 1, 2021 – Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for t |
|
| January 27, 2021 |
Power of Attorney (included on the signature page of this Registration Statement)* As filed with the Securities and Exchange Commission on January 27, 2021 Registration No. |
|
| January 25, 2021 |
SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 888314507 (CUSIP Number) January 15, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| January 21, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 888314606 (CUSIP Number) January 15, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 19, 2021 |
Exhibit 10.2 January 15, 2021 Marc Rubin, M.D. Executive Chairman Titan Pharmaceuticals, Inc. 400 Oyster Point Blvd., Suite 505 South San Francisco, CA 94080 Dear Dr. Rubin: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim”) (the “Placement Agent”) and Titan Pharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), |
|
| January 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 15, 2021 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commi |
|
| January 19, 2021 |
Form of January 15, 2021 Securities Purchase Agreement(28) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 15, 2021, between Titan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond |
|
| January 19, 2021 |
2,725,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-230742 Prospectus Supplement (to Prospectus dated April 24, 2019) 2,725,000 Shares of Common Stock We are offering 2,725,000 shares of our common stock, $0.001 par value per share directly to several institutional investors pursuant to this prospectus supplement and the accompanying prospectus. The offering price of the shares is $3.55. In a co |
|
| January 19, 2021 |
Form of January 2021 Private Placement Warrant(21) Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 19, 2021 |
Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering Exhibit 99.1 Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering South San Francisco, CA – January 15, 2021 – Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $9.7 million of its common stock in a registered direct offering and warra |
|
| January 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 4, 2021 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commis |
|
| December 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 30, 2020 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Comm |
|
| December 31, 2020 |
Other Events, Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 30, 2020 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Comm |
|
| December 17, 2020 |
Other Events, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 15, 2020 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Comm |
|
| December 17, 2020 |
Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Exhibit 99.1 Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements South San Francisco, CA – December 16, 2020 – Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“the “Company”) today announced that on December 15, 2020, it received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq’s minimum bid price re |
|
| December 14, 2020 |
December 11, 2020 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: Titan Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-251187 Ladies and Gentlemen: Titan Pharmaceuticals, Inc. hereby requests that the effective date of the above-captioned Registration Statement be accelerated to 5:00 p.m. on Tuesday, December 15, 2020, or as soon thereaft |
|
| December 8, 2020 |
Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on December 8, 2020 Registration No. |
|
| December 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 1, 2020 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commi |
|
| December 2, 2020 |
our additional Definitive Proxy Materials filed with the SEC on December 2, 2020; and UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, For use of |
|
| December 1, 2020 |
Titan Pharmaceuticals Announces Reverse Stock Split Exhibit 99.1 Titan Pharmaceuticals Announces Reverse Stock Split South San Francisco, CA – November 30, 2020 – Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company’s common stock, which will be effective at 5:00 p.m. Eastern Time on Monday, November 30, 2020. The Company’s stockh |
|
| December 1, 2020 |
Certificate of Amendment to the Restated Certificate of Incorporation dated November 30, 2020(20) Exhibit 3.1 FORM OF CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF TITAN PHARMACEUTICALS, INC. It is hereby certified as follows: 1. The name of the corporation is Titan Pharmaceuticals, Inc. (the “Corporation”). 2. The Corporation hereby amends the provisions of the Corporation’s Amended and Restated Certificate of Incorporation filed with the Secretary of State on Janua |
|
| December 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 30, 2020 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Comm |
|
| November 25, 2020 |
our Definitive Proxy Statement filed with the SEC on November 25, 2020; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary proxy statement ☐ Confidential, For use of |
|
| November 16, 2020 |
Exhibit 10.28 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. THIS ASSET PURCHASE AGREEMENT (the “Agreement”) is made as of October 27, 2020 (the “Effective Date”), by and between TITAN PHARMACEUTICALS, INC., a Delaware corporation (“Titan”), and JT PHARMACEUTICALS, INC., a Delaware |
|
| November 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-13341 Titan Pharmaceut |
|
| November 9, 2020 |
our additional Definitive Proxy Materials filed with the SEC on November 9, 2020; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary proxy statement ¨ Confidential, For use of |
|
| November 9, 2020 |
TTNP / Titan Pharmaceuticals, Inc. / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Titan Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 888314507 (CUSIP Number) October 30, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| November 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 28, 2020 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commi |
|
| November 2, 2020 |
Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering Exhibit 99.1 Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering South San Francisco, CA – October 28, 2020 – Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 80,000,000 units at a price of $0.10 per unit. Each unit issued in the offering consists of one share of common stock and one warrant to purchase on |
|
| November 2, 2020 |
EX-99.2 4 tm2034714d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 TITAN PHARMACEUTICALS COMPLETES DEBT SETTLEMENT WITH MOLTENI AND HORIZON & ACQUISITON OF JT PHARMA’S KAPPA OPIOID AGONIST PEPTIDE, JT-09 South San Francisco, CA – November 2, 2020 – Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced the completion of its agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alit |
|
| November 2, 2020 |
Exhibit 1.1 80,000,000 SHARES of Common Stock and 80,000,000 Warrants (exercisable for 80,000,000 shares) of TITAN PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT October 28, 2020 Maxim Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Maxim Group LLC 405 Lexington Avenue, 2nd Fl. New York, NY 10174 Ladies and Gentlemen: The undersigned, Titan Pharmac |
|
| November 2, 2020 |
our Definitive Proxy Statement filed with the SEC on November 2, 2020; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary proxy statement ☐ Confidential, For use of |
|
| October 29, 2020 |
80,000,000 Units consisting of shares of common stock and warrants Filed Pursuant to Rule 424(b)(5) Registration No. 333-249550 PROSPECTUS 80,000,000 Units consisting of shares of common stock and warrants We are offering 80,000,000 units, with each unit consisting of one share of our common stock, par value $0.001 per share, and one warrant to purchase one share of our common stock. Each share of our common stock is being sold together with a warrant to purcha |
|
| October 28, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 27, 2020 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commi |
|
| October 28, 2020 |
Exhibit 99.1 TITAN PHARMACEUTICALS ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE JT PHARMA’S KAPPA OPIOID AGONIST PEPTIDE, JT-09 - Titan to Develop JT-09 Implant, Using its ProNeura® Long-Term, Continuous Drug Delivery Technology, for the Treatment of Chronic Pruritus - South San Francisco, CA – October 28, 2020 – Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that it has entered into a d |
|
| October 27, 2020 |
Form of Lock-Up and Voting Agreement(25) Exhibit 4.11 LOCK-UP AND VOTING AGREEMENT This Lock-Up and Voting Agreement (this “Lock-Up and Voting Agreement”) is being delivered to you in connection with an understanding by and between Titan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the person or persons named on the signature pages hereto (collectively, the “Holder”). Reference is hereby made to the public offering |
|
| October 27, 2020 |
Exhibit 4.10 Titan Pharmaceuticals, Inc. and Continental Stock Transfer & Trust Company, as Warrant Agent Warrant Agency Agreement Dated as of , 2020 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2020 (“Agreement”), between Titan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Age |
|
| October 27, 2020 |
S-1/A 1 tm2033419-5s1a.htm S-1/A TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 27, 2020 Registration No. 333-249550 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Titan Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware |
|
| October 26, 2020 |
October 26, 2020 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: Titan Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-249550 Ladies and Gentlemen: Titan Pharmaceuticals, Inc. hereby requests that the effective date of the above-captioned Registration Statement be accelerated to 5:00 p.m. on Tuesday, October 27, 2020, or as soon thereafter |
|
| October 26, 2020 |
Form of Lock-Up and Voting Agreement Exhibit 4.11 LOCK-UP AND VOTING AGREEMENT This Lock-Up and Voting Agreement (this “Lock-Up and Voting Agreement”) is being delivered to you in connection with an understanding by and between Titan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the person or persons named on the signature pages hereto (collectively, the “Holder”). Reference is hereby made to the public offering |
|
| October 26, 2020 |
EX-10.1 2 tm2033419d3ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 DEBT SETTLEMENT AND RELEASE AGREEMENT This Debt Settlement and Release Agreement (this “Agreement”) is made and entered into on October 25, 2020 by and among TITAN PHARMACEUTICALS, INC., a Delaware corporation (“Titan”), L. MOLTENI & C. DEI F.LLI ALITTI SOCIETÀ DI ESERCIZIO S.P.A., a company organized and existing under the laws of Italy (“ |
|
| October 26, 2020 |
+As filed with the Securities and Exchange Commission on October 26, 2020 Registration No. |
|
| October 26, 2020 |
Exhibit 4.10 Titan Pharmaceuticals, Inc. and Continental Stock Transfer & Trust Company, as Warrant Agent Warrant Agency Agreement Dated as of , 2020 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2020 (“Agreement”), between Titan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Age |
|
| October 26, 2020 |
Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon Exhibit 99.1 Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon South San Francisco, CA – October 26 2020 – Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura® long-term, continuous drug delivery technology, today announced its entry into an agreement to settle |
|
| October 26, 2020 |
October 26, 2020 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Titan Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended (File No. 333-249550) Ladies and Gentlemen: As the underwriter of the proposed offering of Titan Pharmaceuticals, Inc. (the “Company”), we hereby join the Company’s request for acceleration of the above-referenced Regis |
|
| October 26, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 25, 2020 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-13341 94-3171940 (Commi |
|
| October 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: x Preliminary proxy statement ¨ Confidential, For use of |
